Response of periradicular tissues to growth factors introduced into the surgical site in the root-end filling material.
OBJECTIVE
The objective of this study was to evaluate the healing of the periradicular tissues when exogenous growth factors were delivered to the respected root-end. The healing response was compared with that when Diaket was used as a control.


METHODS
Non-surgical root canal treatment was performed on mandibular teeth in mongrel dogs. Surgical treatment followed and included root-end resection and root-end cavity preparation. Insulin-like growth factor in combination with platelet-derived growth factor, or fibroblast growth factor alone, were then placed in the root-end preparations on a polylactic acid carrier (Atrisorb) with or without the incorporation of the carrier tetracalcium phosphate. The healing was evaluated at 60 days with regard to presence of inflammatory response, bone regeneration, periodontal ligament formation and cementum formation.


RESULTS
Osseous regeneration in the excisional would and periodontal formation were significantly greater when Diaket was used as the root-end filling material. Likewise, cementum deposition occurred significantly more frequently in the Diaket group (P < 0.05). The polylactic carrier Atrisorb remained in the surgical sites for the duration of the study.


CONCLUSIONS
The use of specific growth factors, FGF and a combination of IGF/PDGF, delivered to the prepared root end in a collagen carrier did not initiate the desired periradicular tissue response of regeneration. Diaket, as used in this study, did stimulate a periradicular tissue response compatible with regeneration.
Regan
J D
JD
Department of Restorative Sciences, Baylor College of Dentistry, Dallas, Texas 75246, USA.
Gutmann
J L
JL
Iacopino
A M
AM
Diekwisch
T
T
D000704:Analysis of Variance; D000818:Animals; D001047:Apicoectomy / Q000009:adverse effects; D001729:Bismuth; D001861:Bone Regeneration / Q000187:drug effects*; D002130:Calcium Phosphates; D004285:Dogs; D004337:Drug Carriers; D004338:Drug Combinations; D005346:Fibroblast Growth Factors / Q000008:administration & dosage / Q000494:pharmacology; D006133:Growth Substances / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000494:pharmacology; D019344:Lactic Acid; D010486:Periapical Tissue / Q000293:injuries / Q000502:physiology / Q000601:surgery*; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000494:pharmacology; D011091:Polyesters; D011108:Polymers; D011145:Polyvinyls; D011994:Recombinant Proteins / Q000494:pharmacology; D012184:Retrograde Obturation / Q000009:adverse effects*; D012387:Root Canal Filling Materials; D014945:Wound Healing / Q000187:drug effects*; D015034:Zinc Oxide
D002130:Calcium Phosphates; D004337:Drug Carriers; D004338:Drug Combinations; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D011091:Polyesters; D011108:Polymers; D011145:Polyvinyls; D011994:Recombinant Proteins; D012387:Root Canal Filling Materials; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; D019344:Lactic Acid; C033616:poly(lactide); C014457:bismuth phosphate, copolymers of vinyl acetate, dichlorophen, propionyl-acetophenone, triethanolamine, vinyl chloride, vinylisobutyl ether, zinc oxide drug combination; D005346:Fibroblast Growth Factors; D007334:Insulin-Like Growth Factor I; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C485829:calcium phosphate, dibasic, anhydrous; D015034:Zinc Oxide; D001729:Bismuth